N@N

Joel Beatty Maintained (ACAD) at Buy with Decreased Target to $28 on, May 9th, 2024

Joel Beatty of Baird, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $31 to $28 on, May 9th, 2024.

Joel has made no other calls on ACAD in the last 4 months.

There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 2 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Jay Olson of "Oppenheimer" Maintained at Hold and Held Target at $19 on, Monday, May 6th, 2024
• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $30 on, Tuesday, March 12th, 2024

These are the ratings of the 7 analyists that currently disagree with Joel

---

• Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $27 on, Tuesday, April 30th, 2024
• Tessa Romero of "JP Morgan" Maintained at Buy with Decreased Target to $25 on, Monday, March 25th, 2024
• Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Decreased Target to $30 on, Wednesday, March 13th, 2024
• Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $30 on, Tuesday, March 12th, 2024
• Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $39 on, Tuesday, March 12th, 2024
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $33 on, Tuesday, March 12th, 2024
• Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024

Contributing Sources

---